- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05700422
Nasal Spray Study in Sjogren's Dry Eye Disease
September 2, 2023 updated by: Giacomina Massaro-Giordano, University of Pennsylvania
A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome.
Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study.
If you are eligible to participate in the study and you decide to join, there will be 3 study visits over approximately 1 month.
You will also self-administer the nasal spray at home every day, 2 times a day during this month.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Scheie Eye Institute at the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provide signed written consent prior to study-related procedures
- Be at least 22 years of age at the screening visit
- Have diagnosed moderate to severe Sjogrens Syndrome via blood work or biopsy Category 2 staining score for Conjunctiva based on the Van Bjisterveld and Utrect scale and 3 staining score for cornea based on the NEI scale
- Have been using Cyclosporine or Lifitegrast 3 months
- Be literate and able to complete questionnaires independently
- Be able and willing to use the study drug and participate in all study assessments and visits
- Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug
- Have provided verbal and written informed consent
- If a female is of childbearing potential, they must: use an acceptable means of birth control (acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives, mechanical spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and have a negative urine pregnancy test on Day 1
Exclusion Criteria:
Have undergone previous ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure)
- Have had thermal pulsation or IPL in prior 3 months
- Have used topical ophthalmic corticosteroid therapy in prior 4 weeks
- Have had cataract surgery in the last 6 months
- Have clinically significant ocular trauma.
- Have active ocular Herpes simplex or Herpes Zoster infection
- Have ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
- Have ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
- Have retinal pathology that can limit visual potential and refractive outcomes in the opinion of the investigator
- Have severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
- Have eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
- Have ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
- Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- Have chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to clinically significant risk of increased bleeding.
- Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas
- Be currently treated with nasal continuous positive airway pressure
- Have any untreated nasal infection at Visit 1
- Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal obstruction as confirmed by intranasal examination performed at Visit 1.
- Have a known hypersensitivity to any of the procedural agents or study drug components
- Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period.
- Be a female who is pregnant, nursing, or planning a pregnancy at Visit 1. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal oral, implantable, injectable, or transdermal contraceptives; mechanical spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. The risks of OC-01 among pregnant patients are not known.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OC-01 (varenicline solution) 0.03 mg nasal spray
|
OC-01 (varenicline solution) 0.03 mg nasal spray
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in eye dryness score as measured by the Visual Analogue Scale (VAS)
Time Frame: Baseline to Day 28
|
VAS is a validated, subjective measure for acute and chronic pain.
Patients rate eye dryness on a scale of 1-10 with higher scores indicating high levels of pain.
|
Baseline to Day 28
|
Mean change in cornea staining
Time Frame: Baseline to Day 28
|
The NEI scale is the method that will be used to measure corneal staining using fluorescein strips with a higher score indicating a higher level of staining.
It divides the corneal and conjunctival surfaces to help measure fluorescein uptake.
|
Baseline to Day 28
|
Mean change in conjunctival staining
Time Frame: Baseline to Day 28
|
The Van Bijsterveld and Utrecht scale is the method that will be used to measure conjunctival staining while using lissamine green dye with higher vaules indicating higher levels of staining.
|
Baseline to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in best corrected visual acuity
Time Frame: Baseline to Day 28
|
Baseline to Day 28
|
|
Mean change in dry mouth scale
Time Frame: Baseline to Day 28
|
VAS is a validated, subjective measure for acute and chronic pain.
Patients rate mouth dryness on a scale of 1-10 with higher scores indicating high levels of pain.
|
Baseline to Day 28
|
Incidence and severity of adverse events
Time Frame: Baseline to Day 28
|
Baseline to Day 28
|
|
Mean change in nose dryness scale
Time Frame: Baseline to Day 28
|
VAS is a validated, subjective measure for acute and chronic pain.
Patients rate nose dryness on a scale of 1-10 with higher scores indicating high levels of pain.
|
Baseline to Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2023
Primary Completion (Actual)
August 31, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
January 14, 2023
First Submitted That Met QC Criteria
January 25, 2023
First Posted (Actual)
January 26, 2023
Study Record Updates
Last Update Posted (Actual)
September 6, 2023
Last Update Submitted That Met QC Criteria
September 2, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Syndrome
- Eye Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Sjogren's Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Nicotinic Agonists
- Cholinergic Agonists
- Varenicline
Other Study ID Numbers
- 851655
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionCompletedDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Singapore National Eye CentreCompleted
Clinical Trials on Varenicline Nasal Spray
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Oyster Point Pharma, Inc.Completed
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.Oyster Point Pharma, Inc.Completed
-
Oyster Point Pharma, Inc.CompletedDry Eye Disease (DED)United States
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Brandon BaartmanRecruiting
-
Center for Ophthalmic and Vision Research, LLCCompleted
-
Stephenson Eye AssociatesRecruiting
-
Oyster Point Pharma, Inc.CompletedNeurotrophic KeratopathyUnited States
-
Vance Thompson Vision - MTNot yet recruiting